£
Donate
Donate

Researchers want to find out if a combination of drugs can help treat people with chronic lymphocytic leukaemia (CLL) that has come back after treatment as well as in people where treatment has stopped working.

Project information

Lead researcher

Professor Peter Hillmen, University of Birmingham

Research team
  • A team at University of Birmingham
Related conditions
  • Chronic lymphocytic leukaemia (CLL)
Research type
  • Clinical
Region
  • The Midlands
Grant awarded
  • Clinical Trial
Status
Completed
Funding award date
January 2016
Amount awarded

£65,000

Project completion date
December 2024

The challenge

Doctors know that ibrutinib can help people with chronic lymphocytic leukaemia CLL, by stopping the signals that cancer cells use to divide and grow. In this trial, researchers want to find out how well ibrutinib works when combined with another drug called venetoclax.

Venetoclax acts on a protein called Bcl-2 which is thought to help CLL cells survive and multiply when they should do destroyed. Venetoclax works by blocking Bcl-2 and destroying CLL cells.

The project

In this study researchers are trying to find out if by combining ibrutinib and venetoclax it is possible to create a better and more effective treatment for people with CLL who have seen their disease return, or for people where treatment has stopped working.

Aims

Researchers want to:

  • See how well ibrutinib and venetoclax work together in treating people with CLL.
  • Find out what side-effects people taking ibrutinib and venetoclax may experience.

Help us beat blood cancer by funding a research project

  • Could help eight people newly diagnosed with blood cancer understand their condition.
  • Could help researchers study blood cancer cells to develop new treatments and improve early diagnosis.
  • Could help scientists identify genetic patterns in tumour samples to better understand how genes contribute to the development of blood cancer.
Donate